Collaboration as the key to turning around the drug discovery business

Drugs commercialized today are often discovered in one organization and developed in another. It is a natural outcome of an increasingly expensive and specialized drug discovery process.  

Challenges facing individual researchers and drug discovery organizations could potentially be addressed en masse if collaborative processes and technologies were embraced to realize the economic benefits of well-integrated specialization.

This paper by Barry Bunin, Ph.D. provides insights on collaborating in drug discovery. Please download your copy from the form on the right.